PROF.DR.P.VASANTHI’S UNIT

DR.V.GIRIDHARAN

EVALUATION OF RISK OF ATHEROSCLEROSIS RISK OF ATHEROSCLEROSIS IS

MARKED BY INCREASE IN STIFFNESS PARAMETERS (CAROTID INTIMAL MEDIAL THICKENING) EVEN IN PRESENCE OF A SINGLE METABOLIC SYNDROME RISK AND ZINC DEFICIENCY MAY FURTHER AGGRAVATE THE RISK INDICATING NEED FOR EARLY DIAGNOSIS.

-JAPI MAY 2013 VOL 6

DUPALIMUMAB IN PERSISTANT ASTHMA

 PATIENTS ALREADY ON STEROIDS AND LABAS FOR PERSISTENT, MODERATE-TO-SEVERE ASTHMA AND ELEVATED EOSINOPHILS, DUPILUMAB THERAPY, WAS ASSOCIATED WITH FEWER ASTHMA EXACERBATIONS WHEN LABAS AND INHALED GLUCOCORTICOIDS WERE WITHDRAWN, WITH IMPROVED LUNG FUNCTION AND REDUCED LEVELS OF TH2-ASSOCIATED INFLAMMATORY MARKERS

- NEJM MAY 2013

ATORVASTATIN 40 Vs 80 THE CURE-ACS TRIAL INDICATED THAT

ATORVASTATIN 80 MG WAS MORE EFFECTIVE THAN ATORVASTATIN 40 MG IN

TERMS OF REDUCTION IN LDL CHOLESTEROL AND WAS AS SAFE AND WELL TOLERATED AS 40 MG DOSE IN INDIAN PATIENTS WITH ACS.

-JAPI FEB 2013 VOL 61

APIXABAN FOR EXTENDED TRT OF THROMBOEMBOLISM

EXTENDED ANTICOAGULATION WITH APIXABAN AT EITHER A TREATMENT DOSE (5 MG) OR A THROMBOPROPHYLACTIC DOSE (2.5 MG) REDUCED THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM WITHOUT INCREASING THE RATE OF MAJOR BLEEDING.

-NEJM FEB 2013

PRASUGREL Vs CLOPIDOGREL IN ACS PATIENTS UNDERGOING PCIPRASUGREL IS MORE EFFECTIVE THAN

CLOPIDOGREL AS EVIDENT BY INHIBITION OF PLATELET AGGREGATION. PATIENTS ON CLOPIDOGREL ARE LIKELY TO HAVE POOR RESPONSE TO THERAPY AS COMPARED TO PRASUGREL. BOTH ARE WERE WELL TOLERATED AND HAVE COMPARABLE SAFETY PROFILE.

-JAPI 2013 VOL 61

RACECADOTRIL Vs OCTREOTIDE IN ACUTE INFECTIVE DIARRHOEA SINGLE DOSE OF OCTREOTIDE IS BETTER

THAN RACECADOTRIL IN TERMS OF FREQUENCY, QUANTITY AND CONSISTENCY OF STOOLS PASSED. THE FLUID REQUIREMENT WAS ALSO LESS. MORE TRIALS ARE NEEDED BEFORE OCTREOTIDE BECOMES A STANDARD THERAPY IN ACUTE INFECTIVE DIARRHOEA

JAPI NOV 12 VOL 60

PEGINESATIDE –HEMODIALYSIS

PEGINESATIDE, ADMINISTERED MONTHLY, WAS AS EFFECTIVE AS EPOETIN, ADMINISTERED ONE TO THREE TIMES PER WEEK, IN MAINTAINING HEMOGLOBIN LEVELS IN PATIENTS UNDERGOING HEMODIALYSIS.

N ENGL J MED 2013; 368:307-319JANUARY 24, 2013

COMBINATION ANTIFUNGAL THERAPY FOR CRYPTOCOCCAL MENINGITISAMPHOTERICIN B PLUS FLUCYTOSINE, AS

COMPARED WITH AMPHOTERICIN B ALONE, IS ASSOCIATED WITH IMPROVED SURVIVAL AMONG PATIENTS WITH CRYPTOCOCCAL MENINGITIS

N ENGL J MED 2013; 368:1291-1302APRIL 4, 2013

BIVENTRICULAR PACING IN AV BLOCK BIVENTRICULAR PACING WAS SUPERIOR TO

CONVENTIONAL RIGHT VENTRICULAR PACING IN PATIENTS WITH ATRIOVENTRICULAR BLOCK AND LEFT VENTRICULAR SYSTOLIC DYSFUNCTION WITH NYHA CLASS I, II, OR III HEART FAILURE.

-N ENGL J MED 2013; 368:1585-1593APRIL 25, 2013

MUC5B PROMOTOR POLYMORPHISM AND ILD

THE MUC5B PROMOTER POLYMORPHISM WAS FOUND TO BE ASSOCIATED WITH INTERSTITIAL LUNG DISEASE IN THE GENERAL POPULATION. ALTHOUGH THIS ASSOCIATION WAS MORE APPARENT IN OLDER PERSONS, IT DID NOT APPEAR TO BE INFLUENCED BY CIGARETTE SMOKING.

-PUBLISHED ON MAY 21, 2013, AT NEJM.ORG

REDUCED PARIETAL LOBE THICKNESS AND VALPROATE

SODIUM VALPROATE USE IN EPILEPSY IS ASSOCIATED WITH PARIETAL LOBE THINNING, REDUCED TOTAL BRAIN VOLUME, AND REDUCED WHITE MATTER VOLUME.

-NEUROLOGY MAY 14, 2013

IRON DEFICIENCY AND SUBCLINICAL HYPOTHYROIDSMSUBCLINICAL HYPOTHYROIDISM WAS

INVESTIGATED IN IRON-DEFICIENT PATIENTS WITH NO ACCEPTABLE RESPONSE TO IRON SALT ALONE. A COMBINATION OF LEVOTHYROXINE AND IRON SALT IS BETTER THAN EACH ONE ALONE.

AMERICAN JOURNAL OF MEDICINE

MAY 2013

MR AND NON CARDIAC SURGERYPATIENTS UNDERGOING NONCARDIAC

SURGERY WITH SIGNIFICANT ISCHEMIC MITRAL REGURGITATION ARE AT HIGHER RISK OF A COMPOSITE ADVERSE POSTOPERATIVE OUTCOME, INCLUDING SHORT-TERM MORTALITY, HEART FAILURE, MYOCARDIAL INFARCTION, AND STROKE.

AMERICAN JOURNAL OF MEDICINE APR 15 2013

ECULIZUMAB AND ATYPICAL HUS

ECULIZUMAB INHIBITED COMPLEMENT-MEDIATED THROMBOTIC MICROANGIOPATHY AND WAS ASSOCIATED WITH SIGNIFICANT TIME-DEPENDENT IMPROVEMENT IN RENAL FUNCTION IN PATIENTS WITH ATYPICAL HEMOLYTIC–UREMIC SYNDROME.

- N ENGL J MED 2013; 368:2169-2181JUNE 6, 2013

PRONE POSITIONING AND ARDS

IN PATIENTS WITH SEVERE ARDS, EARLY APPLICATION OF PROLONGED PRONE-POSITIONING SESSIONS SIGNIFICANTLY DECREASED 28-DAY AND 90-DAY MORTALITY.

 PUBLISHED ON MAY 20, 2013, AT NEJM.ORG.

CRIZOTINIB Vs CHEMO IN ALK +VE LUNG CANCER CRIZOTINIB IS SUPERIOR TO STANDARD

CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED, ADVANCED NON–SMALL-CELL LUNG CANCER WITH ALKREARRANGEMENT

-NEJM JUNE 2013